NCT04486625View on ClinicalTrials.gov

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

September 20, 2021

Study Completion Date

October 18, 2021

Conditions
Renal Insufficiency
Interventions
DRUG

Aztreonam-Avibactam

500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours

DRUG

Aztreonam-Avibactam

675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours

Trial Locations (1)

55114

Prism Research LLC dba Nucleus Network, Saint Paul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04486625 - Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment | Biotech Hunter | Biotech Hunter